Low-Grade Glioma Global Market Report 2025

The low-grade glioma market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to increased awareness of brain tumors, higher funding in oncology driving research, a rise in orphan drug designations, the expansion of telemedicine, and improved healthcare access.

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.86 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to a rising aging population, increasing healthcare expenditure, a growing prevalence of brain tumors, expanding government initiatives, and a higher incidence of high-grade gliomas. Key trends include advancements in imaging technologies, the development of radiation therapies, the introduction of new chemotherapy regimens, the expansion of clinical trials, and the integration of immunotherapy.

The increasing incidence of brain tumors is driving the growth of the low-grade glioma market. Brain tumors, abnormal growths of cells in the brain or surrounding tissues, can be benign or malignant. The rising occurrence of brain tumors is linked to factors such as radiation exposure, environmental pollutants, genetic predisposition, and aging. Low-grade glioma treatments utilize advanced diagnostic techniques and targeted therapies including surgery, radiation, and chemotherapy to slow tumor progression, preserve neurological function, and improve patient outcomes. Early detection and personalized treatment approaches are crucial for managing brain tumors with similar growth patterns. For instance, in October 2023, The Central Brain Tumor Registry of the United States (CBTRUS) reported that the worldwide incidence of primary malignant brain tumors in 2022 was approximately 3.5 per 100,000 people, with higher rates in high-income countries (4.9 per 100,000) compared to low-middle-income (2.4 per 100,000) and low-income countries. This increasing prevalence of brain tumors is propelling the expansion of the low-grade glioma market.

Leading companies in the low-grade glioma market are advancing treatment options by integrating combination therapies and targeted therapies, such as genetic alteration drugs, to improve patient outcomes. Genetic alteration drugs are designed to target and modify specific genetic mutations or abnormalities that drive uncontrolled cell growth, making them a promising approach for treating conditions such as low-grade glioma. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is specifically designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) characterized by BRAF gene alterations. It offers a convenient once-weekly oral treatment, addressing an urgent need for pediatric LGG patients with limited prior treatment options.

In July 2024, Ipsen Biopharmaceuticals Inc., a US-based pharmaceutical company, partnered with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for pediatric low-grade glioma (pLGG) with BRAF mutations. This collaboration aims to expand global access to the treatment while leveraging Ipsen’s oncology expertise and international reach to accelerate regulatory approvals and commercial efforts outside the United States. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing targeted therapies for pediatric brain tumors, particularly low-grade glioma.

Major players in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, and Sunesis Pharmaceuticals Inc.

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in low-grade glioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the low-grade glioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Low-grade gliomas are a type of brain tumor that originates from glial cells, which support and insulate nerve cells in the brain. These tumors are characterized by slow growth and generally less aggressive behavior than high-grade gliomas, though they can still cause significant neurological symptoms and may require treatment.

The primary drug types for low-grade glioma include trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication that treats certain cancers by inhibiting the MEK1/2 proteins involved in cancer cell growth. Treatment for low-grade glioma typically involves a combination of surgery, chemotherapy, and radiation. Medications are administered through various routes, including oral and topical delivery, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The low-grade glioma market research report is one of a series of new reports that provides low-grade glioma market statistics, including the low-grade glioma industry global market size, regional shares, competitors with the low-grade glioma market share, detailed low-grade glioma market segments, market trends, and opportunities, and any further data you may need to thrive in the low-grade glioma industry. This low-grade glioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.